investigates the interplay between immune cells and various disease including cancer and inflammation in vivo. Our aim is to understand the mechanism that control immunity and to identify novel targets for cancer immunotherapy.
We focussing on (1) CAR t-cells and (2) neutrophile extracellular traps (NETs).
Pediatric Tumors are particularly immunogenic. We develop and implement cutting-edge CAR t-cell technologies to control or eliminate cancer and to modulate the immune system. In our lab we combine and into novel therapeutic strategies which will ultimately benefit children suffering from cancer or immune disease.
NETs confer protection against infections, but also drive inflammation and immunopathology.
News & Events
Therapeutic Targeting of Neutrophil Extracellular Traps Improves Primary and Secondary Intention Wound Healing in Mice
Frontiers Immunology: Primary and secondary intention wound healing is improved by targeting NETs through DNase1 treatment or genetic KO, as assessed by wound closure time and scar appearances. Additionally, wound stability was not affected by DNASE treatment. The results suggest that overall wound healing is accelerated and DNase1 appears to be a promising option to reduce scar formation; which should be evaluated in humans.